- Full Text
- Scholarly Journal
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
PDF
CiteCite
Copy URL
https://www.proquest.com/scholarly-journals/zanidatamab-plus-chemotherapy-as-first-line/docview/3225699460/se-2?accountid=208611
PrintAll Options